353 Anti–Saccharomyces Cerevisiae Antibodies (ASCA) Are Biomarkers of Moderate-To-Severe Hidradenitis Suppurativa (HS), but Not of Severe Plaque Psoriasis: Results From a Prospective, Multicenter Study

Journal of Investigative Dermatology - United Kingdom
doi 10.1016/j.jid.2017.07.548
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients With Moderate-To-Severe Plaque Psoriasis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Costs of Treatment in Patients With Moderate to Severe Plaque Psoriasis

Archives of Dermatology
2004English

Severe Hidradenitis Suppurativa Treated With Adalimumab

Archives of Dermatology
2006English

Efficacy and Safety of Mirikizumab (LY3074828) in the Treatment of Moderate-To-Severe Plaque Psoriasis: Results From a Randomised Phase 2 Study

British Journal of Dermatology
DermatologyMedicine
2019English

Population Pharmacokinetics of Brodalumab in Patients With Moderate to Severe Plaque Psoriasis

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2019English

Pharmacokinetics and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: Results From a Phase 2 Open-Label Study

Journal of the American Academy of Dermatology
Dermatology
2020English

New Polymorphisms Associated With Response to Anti-TNF Drugs in Patients With Moderate-To-Severe Plaque Psoriasis

Pharmacogenomics Journal
Molecular MedicineGeneticsPharmacology
2016English

Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: Results of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study

SKIN The Journal of Cutaneous Medicine
2019English

The Experience of Pain and Redness in Patients With Moderate to Severe Plaque Psoriasis

Journal of Dermatological Treatment
Dermatology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy